161 related articles for article (PubMed ID: 12481437)
1. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
Mulryan K; Ryan MG; Myers KA; Shaw D; Wang W; Kingsman SM; Stern PL; Carroll MW
Mol Cancer Ther; 2002 Oct; 1(12):1129-37. PubMed ID: 12481437
[TBL] [Abstract][Full Text] [Related]
2. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.
Harrop R; Ryan MG; Myers KA; Redchenko I; Kingsman SM; Carroll MW
Cancer Immunol Immunother; 2006 Sep; 55(9):1081-90. PubMed ID: 16311730
[TBL] [Abstract][Full Text] [Related]
3. Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors.
Jiang HR; Gilham DE; Mulryan K; Kirillova N; Hawkins RE; Stern PL
J Immunol; 2006 Oct; 177(7):4288-98. PubMed ID: 16982863
[TBL] [Abstract][Full Text] [Related]
4. 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2007 Sep; 7(9):1463-9. PubMed ID: 17727334
[TBL] [Abstract][Full Text] [Related]
5. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the murine 5T4 oncofoetal antigen: a target for immunotherapy in cancer.
Woods AM; Wang WW; Shaw DM; Ward CM; Carroll MW; Rees BR; Stern PL
Biochem J; 2002 Aug; 366(Pt 1):353-65. PubMed ID: 12003637
[TBL] [Abstract][Full Text] [Related]
7. Murine responses to recombinant MVA versus ALVAC vaccines against tumor-associated antigens, gp100 and 5T4.
Hanwell DG; McNeil B; Visan L; Rodrigues L; Dunn P; Shewen PE; Macallum GE; Turner PV; Vogel TU
J Immunother; 2013 May; 36(4):238-47. PubMed ID: 23603858
[TBL] [Abstract][Full Text] [Related]
8. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
Cappuccini F; Pollock E; Stribbling S; Hill AVS; Redchenko I
Oncotarget; 2017 Jul; 8(29):47474-47489. PubMed ID: 28537896
[TBL] [Abstract][Full Text] [Related]
9. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
Carroll MW; Overwijk WW; Chamberlain RS; Rosenberg SA; Moss B; Restifo NP
Vaccine; 1997 Mar; 15(4):387-94. PubMed ID: 9141209
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.
Amato RJ; Stepankiw M
Future Oncol; 2012 Mar; 8(3):231-7. PubMed ID: 22409460
[TBL] [Abstract][Full Text] [Related]
11. Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Scurr M; Pembroke T; Bloom A; Roberts D; Thomson A; Smart K; Bridgeman H; Adams R; Brewster A; Jones R; Gwynne S; Blount D; Harrop R; Wright M; Hills R; Gallimore A; Godkin A
JAMA Oncol; 2017 Oct; 3(10):e172579. PubMed ID: 28880972
[TBL] [Abstract][Full Text] [Related]
12. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
13. CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells.
Elkord E; Burt DJ; Drijfhout JW; Hawkins RE; Stern PL
Cancer Immunol Immunother; 2008 Jun; 57(6):833-47. PubMed ID: 18004564
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
[TBL] [Abstract][Full Text] [Related]
15. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice.
Bohnen C; Wangorsch A; Schülke S; Nakajima-Adachi H; Hachimura S; Burggraf M; Süzer Y; Schwantes A; Sutter G; Waibler Z; Reese G; Toda M; Scheurer S; Vieths S
Allergy; 2013 Aug; 68(8):1021-8. PubMed ID: 23909913
[TBL] [Abstract][Full Text] [Related]
18. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
[TBL] [Abstract][Full Text] [Related]
19. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P
J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436
[TBL] [Abstract][Full Text] [Related]
20. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.
Tykodi SS; Thompson JA
Expert Opin Biol Ther; 2008 Dec; 8(12):1947-53. PubMed ID: 18990081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
